JP Morgan Cuts IDEXX Laboratories (IDXX) Price Target to $750

JP Morgan has reiterated its Overweight rating on IDEXX Laboratories, Inc. (NASDAQ: IDXX) on October 16, 2026, lowering its price target from $775 to $750. This new target suggests a significant gap as the stock is recently trading at about $560.39, which is approximately 25.3% below the new target price.

Other Institutional Activity in IDEXX Laboratories

Blackrock Inc. reduced its stake in IDEXX, selling 195,763 shares and ending with 8,170,178 shares valued at about $4.58 billion. Vanguard Capital Management LLC also trimmed its holdings, decreasing by 30,057 shares to a total of 5,152,213 shares worth approximately $2.89 billion. Meanwhile, State Street Corporation added 74,584 shares, bringing its total to 3,748,660 shares valued at around $2.10 billion. Invesco Ltd. increased its position by 261,619 shares, totaling 3,611,416 shares valued at about $2.02 billion.

IDEXX Laboratories, Inc. Stock Up 9.5%

The stock is currently trading around $560.39, which is below JP Morgan's new price target of $750. This price point is important as it indicates potential upside if the stock moves closer to the target. The shares have been fluctuating, and this adjustment in the target reflects market conditions and the company's performance.

Recent Earnings

IDEXX Laboratories reported trailing twelve-month revenue of approximately $4.55 billion, with an impressive net margin of 25.0%. The company also has a return on equity of 74.2%, showcasing its efficiency in generating profits from its equity. The next earnings report is scheduled for November 2, 2026.

Insider Buying and Selling at IDEXX Laboratories, Inc.

Several insiders sold shares recently. On February 26, 2026, Officer Nimrata K. Hunt sold 2,693 shares at an average price of $661.54, totaling about $1.78 million. CEO Jonathan Jay Mazelsky sold 23,326 shares, valued at approximately $15.34 million, on the same date. Hunt made another sale of 1,758 shares on March 3, 2026, at an average price of $634.57, worth about $1.12 million. Director Lawrence D. Kingsley sold 2,203 shares on September 4, 2026, at an average price of $532.08, totaling around $1.17 million.

Analysts Set New Price Targets

On October 16, 2026, JP Morgan maintained its Overweight rating on IDEXX Laboratories, lowering its price target from $775 to $750. Other firms have also provided insights; Barclays maintained an Overweight rating with a target of $710, and both UBS and Citigroup kept their Neutral ratings with targets of $670. The consensus among analysts indicates a moderate outlook, with various price targets reflecting differing expectations for the stock's performance.

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops and sells products for veterinary, livestock, and water testing industries. It operates through segments focusing on companion animals, water quality, and livestock. The company is known for its innovation in diagnostics and research, making it a key player in the healthcare sector.

Bottom Line

Investors should keep an eye on IDEXX Laboratories as it approaches its next earnings report on November 2, 2026. With JP Morgan's recent rating and price target adjustment, there may be further developments in how the market perceives the stock's potential.